Cargando…

Analysis of the expression levels of chemerin, ox‐LDL, MMP‐9, and PAPP‐A in ICVD patients and their relationship with the severity of neurological impairment

OBJECTIVE: The study aimed to analyze the relationship between expression levels of chemerin, oxidized low density lipoprotein (ox‐LDL), matrix metalloproteinase 9 (MMP‐9) and pregnancy associated plasma protein A (PAPP‐A) in ischemic cerebrovascular disease (ICVD) patients and the relationship betw...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Jianpu, Wang, Lixuan, Zhang, Liran, Hong, Zhen, Xia, Ruixue, Zhao, Zeyu, Zhang, Leguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304843/
https://www.ncbi.nlm.nih.gov/pubmed/35620813
http://dx.doi.org/10.1002/brb3.2613
_version_ 1784752181919875072
author Jia, Jianpu
Wang, Lixuan
Zhang, Liran
Hong, Zhen
Xia, Ruixue
Zhao, Zeyu
Zhang, Leguo
author_facet Jia, Jianpu
Wang, Lixuan
Zhang, Liran
Hong, Zhen
Xia, Ruixue
Zhao, Zeyu
Zhang, Leguo
author_sort Jia, Jianpu
collection PubMed
description OBJECTIVE: The study aimed to analyze the relationship between expression levels of chemerin, oxidized low density lipoprotein (ox‐LDL), matrix metalloproteinase 9 (MMP‐9) and pregnancy associated plasma protein A (PAPP‐A) in ischemic cerebrovascular disease (ICVD) patients and the relationship between the mentioned indicators and the degree of neurological impairment. METHODS: From January 2020 to February 2021, a total of 328 cases of ICVD patients were admitted to our hospital, and 240 cases of healthy people (control group) were prospectively recruited into this study. The 328 patients were divided into 2 ischemic subtypes, with 233 cases as acute cerebral infarction (ACI) and 95 cases as transient ischemic attack (TIA). Laboratory tests were compared among the groups. Spearman rank correlation was used to analyze the correlation between chemerin, ox‐LDL, MMP‐9, PAPP‐A levels and neurological deficit. Unconditional logisitic regression was used to analyze the risk factors for neurological deficits. RESULTS: The high density lipoprotein cholesterol (HDL‐C), fasting plasma glucose (FPG), chemerin, ox‐LDL, MMP‐9, and PPAP‐A levels in the ACI group were significantly higher than those in the TIA group and control group (p < 0.05, respectively), while the levels of the mentioned indicators in the TIA group were significantly higher than those in control group (p < 0.05, respectively). The levels of the given indicators decreased successively in the severe, moderate, and mild neurological deficits population and control group, with statistical difference. Spearman rank correlation analysis showed that chemerin, ox‐LDL, MMP‐9, and PPAP‐A levels were positively correlated with the degree of neurological deficit in ICVD patients. Unconditional logistic regression analysis showed that chemerin, ox‐LDL, MMP‐9, and PPAP‐A were the independent risk factors for neurological deficit in patients with ICVD. CONCLUSION: LDL‐C, FPG, chemerin, ox‐LDL, MMP‐9, and PPAP‐A were highly expressed in ACI and neurological deficit patients. Chemerin, ox‐LDL, MMP‐9, and PPAP‐A may be the independent risk factors for neurological deficit in patients with ICVD.
format Online
Article
Text
id pubmed-9304843
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93048432022-07-26 Analysis of the expression levels of chemerin, ox‐LDL, MMP‐9, and PAPP‐A in ICVD patients and their relationship with the severity of neurological impairment Jia, Jianpu Wang, Lixuan Zhang, Liran Hong, Zhen Xia, Ruixue Zhao, Zeyu Zhang, Leguo Brain Behav Original Articles OBJECTIVE: The study aimed to analyze the relationship between expression levels of chemerin, oxidized low density lipoprotein (ox‐LDL), matrix metalloproteinase 9 (MMP‐9) and pregnancy associated plasma protein A (PAPP‐A) in ischemic cerebrovascular disease (ICVD) patients and the relationship between the mentioned indicators and the degree of neurological impairment. METHODS: From January 2020 to February 2021, a total of 328 cases of ICVD patients were admitted to our hospital, and 240 cases of healthy people (control group) were prospectively recruited into this study. The 328 patients were divided into 2 ischemic subtypes, with 233 cases as acute cerebral infarction (ACI) and 95 cases as transient ischemic attack (TIA). Laboratory tests were compared among the groups. Spearman rank correlation was used to analyze the correlation between chemerin, ox‐LDL, MMP‐9, PAPP‐A levels and neurological deficit. Unconditional logisitic regression was used to analyze the risk factors for neurological deficits. RESULTS: The high density lipoprotein cholesterol (HDL‐C), fasting plasma glucose (FPG), chemerin, ox‐LDL, MMP‐9, and PPAP‐A levels in the ACI group were significantly higher than those in the TIA group and control group (p < 0.05, respectively), while the levels of the mentioned indicators in the TIA group were significantly higher than those in control group (p < 0.05, respectively). The levels of the given indicators decreased successively in the severe, moderate, and mild neurological deficits population and control group, with statistical difference. Spearman rank correlation analysis showed that chemerin, ox‐LDL, MMP‐9, and PPAP‐A levels were positively correlated with the degree of neurological deficit in ICVD patients. Unconditional logistic regression analysis showed that chemerin, ox‐LDL, MMP‐9, and PPAP‐A were the independent risk factors for neurological deficit in patients with ICVD. CONCLUSION: LDL‐C, FPG, chemerin, ox‐LDL, MMP‐9, and PPAP‐A were highly expressed in ACI and neurological deficit patients. Chemerin, ox‐LDL, MMP‐9, and PPAP‐A may be the independent risk factors for neurological deficit in patients with ICVD. John Wiley and Sons Inc. 2022-05-26 /pmc/articles/PMC9304843/ /pubmed/35620813 http://dx.doi.org/10.1002/brb3.2613 Text en © 2022 The Authors. Brain and Behavior published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Jia, Jianpu
Wang, Lixuan
Zhang, Liran
Hong, Zhen
Xia, Ruixue
Zhao, Zeyu
Zhang, Leguo
Analysis of the expression levels of chemerin, ox‐LDL, MMP‐9, and PAPP‐A in ICVD patients and their relationship with the severity of neurological impairment
title Analysis of the expression levels of chemerin, ox‐LDL, MMP‐9, and PAPP‐A in ICVD patients and their relationship with the severity of neurological impairment
title_full Analysis of the expression levels of chemerin, ox‐LDL, MMP‐9, and PAPP‐A in ICVD patients and their relationship with the severity of neurological impairment
title_fullStr Analysis of the expression levels of chemerin, ox‐LDL, MMP‐9, and PAPP‐A in ICVD patients and their relationship with the severity of neurological impairment
title_full_unstemmed Analysis of the expression levels of chemerin, ox‐LDL, MMP‐9, and PAPP‐A in ICVD patients and their relationship with the severity of neurological impairment
title_short Analysis of the expression levels of chemerin, ox‐LDL, MMP‐9, and PAPP‐A in ICVD patients and their relationship with the severity of neurological impairment
title_sort analysis of the expression levels of chemerin, ox‐ldl, mmp‐9, and papp‐a in icvd patients and their relationship with the severity of neurological impairment
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304843/
https://www.ncbi.nlm.nih.gov/pubmed/35620813
http://dx.doi.org/10.1002/brb3.2613
work_keys_str_mv AT jiajianpu analysisoftheexpressionlevelsofchemerinoxldlmmp9andpappainicvdpatientsandtheirrelationshipwiththeseverityofneurologicalimpairment
AT wanglixuan analysisoftheexpressionlevelsofchemerinoxldlmmp9andpappainicvdpatientsandtheirrelationshipwiththeseverityofneurologicalimpairment
AT zhangliran analysisoftheexpressionlevelsofchemerinoxldlmmp9andpappainicvdpatientsandtheirrelationshipwiththeseverityofneurologicalimpairment
AT hongzhen analysisoftheexpressionlevelsofchemerinoxldlmmp9andpappainicvdpatientsandtheirrelationshipwiththeseverityofneurologicalimpairment
AT xiaruixue analysisoftheexpressionlevelsofchemerinoxldlmmp9andpappainicvdpatientsandtheirrelationshipwiththeseverityofneurologicalimpairment
AT zhaozeyu analysisoftheexpressionlevelsofchemerinoxldlmmp9andpappainicvdpatientsandtheirrelationshipwiththeseverityofneurologicalimpairment
AT zhangleguo analysisoftheexpressionlevelsofchemerinoxldlmmp9andpappainicvdpatientsandtheirrelationshipwiththeseverityofneurologicalimpairment